Please wait while the formulary information is being retrieved.
FLEBOGAMMA DIF (IMMUNE GLOBULIN,GAMMA(IGG))
- Primary immune deficiency disorder
- Agammaglobulinemia
- Common variable agammaglobulinemia
- Idiopathic thrombocytopenic purpura
- Severe combined immunodeficiency disease
- Wiskott-aldrich syndrome
- X-linked agammaglobulinemia
10 % intravenous solution
- Dosage information is not available
5 % intravenous solution
- Dosage information is not available
Agammaglobulinemia
- Infuse 300 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route once
- Infuse 300 mg/kg by intravenous route every 3 weeks
- Infuse 300 mg/kg by intravenous route every 4 weeks
- Infuse 600 mg/kg by intravenous route once
- Infuse 600 mg/kg by intravenous route every 3 weeks
- Infuse 600 mg/kg by intravenous route every 4 weeks
Common variable agammaglobulinemia
- Infuse 300 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route once
- Infuse 300 mg/kg by intravenous route every 3 weeks
- Infuse 300 mg/kg by intravenous route every 4 weeks
- Infuse 600 mg/kg by intravenous route once
- Infuse 600 mg/kg by intravenous route every 3 weeks
- Infuse 600 mg/kg by intravenous route every 4 weeks
Idiopathic thrombocytopenic purpura
- Infuse 1 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 1 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min for 2 days
Primary immune deficiency disorder
- Infuse 300 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route once
- Infuse 300 mg/kg by intravenous route every 3 weeks
- Infuse 300 mg/kg by intravenous route every 4 weeks
- Infuse 600 mg/kg by intravenous route once
- Infuse 600 mg/kg by intravenous route every 3 weeks
- Infuse 600 mg/kg by intravenous route every 4 weeks
Severe combined immunodeficiency disease
- Infuse 300 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route once
- Infuse 300 mg/kg by intravenous route every 3 weeks
- Infuse 300 mg/kg by intravenous route every 4 weeks
- Infuse 600 mg/kg by intravenous route once
- Infuse 600 mg/kg by intravenous route every 3 weeks
- Infuse 600 mg/kg by intravenous route every 4 weeks
Wiskott-aldrich syndrome
- Infuse 300 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route once
- Infuse 300 mg/kg by intravenous route every 3 weeks
- Infuse 300 mg/kg by intravenous route every 4 weeks
- Infuse 600 mg/kg by intravenous route once
- Infuse 600 mg/kg by intravenous route every 3 weeks
- Infuse 600 mg/kg by intravenous route every 4 weeks
X-linked agammaglobulinemia
- Infuse 300 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route once
- Infuse 300 mg/kg by intravenous route every 3 weeks
- Infuse 300 mg/kg by intravenous route every 4 weeks
- Infuse 600 mg/kg by intravenous route once
- Infuse 600 mg/kg by intravenous route every 3 weeks
- Infuse 600 mg/kg by intravenous route every 4 weeks
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- Proquad (pf)
- varicella virus vacc live (PF)
- Varivax (pf)
- yellow fever vaccine live (PF)
- Yf-vax (pf)
Contraindicated
- None
Severe
Moderate
- Activella
- Alora
- Altavera (28)
- Alyacen 1/35 (28)
- Alyacen 7/7/7 (28)
- Amethia
- Amethia Lo
- Amethyst
- Angeliq
- Apri
- Aranelle (28)
- Aubra
- Aviane
- Azurette (28)
- Balziva (28)
- Beyaz
- Brevicon (28)
- Briellyn
- Camrese
- Camrese Lo
- Caziant (28)
- Cenestin
- Chateal
- Climara
- Climara Pro
- Combipatch
- conj estrogens-bazedoxifene
- conjugated estrogens
- Covaryx
- Covaryx H.s.
- Cryselle (28)
- Cyclafem 1/35 (28)
- Cyclafem 7/7/7 (28)
- Cyclessa (28)
- Dasetta 1/35 (28)
- Dasetta 7/7/7 (28)
- Daysee
- Delestrogen
- Depo-estradiol
- desog-e.estradiol/e.estradiol
- Desogen
- desogestrel-ethinyl estradiol
- Divigel
- drospirenone-e.estradiol-lm.FA
- drospirenone-estradiol
- drospirenone-ethinyl estradiol
- Duavee
- Eemt
- Eemt Hs
- Elestrin
- Elinest
- Emoquette
- Enjuvia
- Enpresse
- Enskyce
- Estarylla
- esterified estrogens
- Estrace
- estradiol
- estradiol acetate
- estradiol cypionate
- Estradiol Transdermal Patch
- estradiol valerate
- estradiol valerate-dienogest
- estradiol-levonorgestrel
- estradiol-norethindrone acet
- estradiol-norgestimate
- Estrasorb
- Estring
- Estrogel
- estrogens-methyltestosterone
- estropipate
- Estrostep Fe-28
- ethynodiol diac-eth estradiol
- etonogestrel-ethinyl estradiol
- Evamist
- Falmina (28)
- Femcon Fe
- Femhrt Low Dose
- Femring
- Generess Fe
- Gianvi (28)
- Gildagia
- Gildess
- Gildess Fe
- Introvale
- Jinteli
- Jolessa
- Junel 1.5/30 (21)
- Junel 1/20 (21)
- Junel Fe 1.5/30 (28)
- Junel Fe 1/20 (28)
- Kariva (28)
- Kelnor 1/35 (28)
- Kurvelo
- L norgest&E estradiol-E estrad
- Larin 1/20 (21)
- Larin Fe
- Leena 28
- Lessina
- Levonest (28)
- levonorg-eth estrad triphasic
- levonorgestrel-ethinyl estrad
- Levora 0.15/30 (28)
- Levora-28
- Lo Loestrin Fe
- Loestrin 1.5/30 (21)
- Loestrin 1/20 (21)
- Loestrin Fe 1.5/30 (28)
- Loestrin Fe 1/20 (28)
- Lomedia 24 Fe
- Loryna (28)
- Loseasonique
- Low-ogestrel (28)
- Lutera (28)
- Marlissa
- Menest
- Menostar
- Microgestin 1.5/30 (21)
- Microgestin 1/20 (21)
- Microgestin Fe 1.5/30 (28)
- Microgestin Fe 1/20 (28)
- Mimvey
- Minastrin 24 Fe
- Minivelle
- Mircette (28)
- Modicon (28)
- Mono-linyah
- Mononessa (28)
- Myzilra
- Natazia
- Necon 0.5/35 (28)
- Necon 1/35 (28)
- Necon 1/50 (28)
- Necon 10/11 (28)
- Necon 7/7/7 (28)
- norelgestrom-ethinyl estradiol
- noreth-ethinyl estradiol-iron
- norethin-e.estradiol triphasic
- norethin-eth estrad biphasic
- norethindrone ac-eth estradiol
- norethindrone-e.estradiol-iron
- norethindrone-ethin estradiol
- norethindrone-mestranol
- norgestimate-ethinyl estradiol
- norgestrel-ethinyl estradiol
- Norinyl 1+35 (28)
- Norinyl 1+50 (28)
- Nortrel 0.5/35 (28)
- Nortrel 1/35 (21)
- Nortrel 1/35 (28)
- Nortrel 7/7/7 (28)
- Nuvaring
- Ocella
- Ogen 2.5
- Ogestrel (28)
- Orsythia
- Ortho Evra
- Ortho Tri-cyclen (28)
- Ortho Tri-cyclen Lo (28)
- Ortho-cept (28)
- Ortho-cyclen (28)
- Ortho-novum 1/35 (28)
- Ortho-novum 7/7/7 (28)
- Ovcon-35 (28)
- Philith
- Pimtrea (28)
- Pirmella
- Portia
- Prefest
- Premarin
- Previfem
- Quartette
- Quasense
- Reclipsen (28)
- Safyral
- Seasonique
- Sprintec (28)
- Sronyx
- Syeda
- synthetic conj estrogens A
- synthetic conj estrogens B
- Tilia Fe
- Tri-estarylla
- Tri-legest Fe
- Tri-linyah
- Tri-norinyl (28)
- Tri-previfem (28)
- Tri-sprintec (28)
- Trinessa (28)
- Trivora (28)
- Vagifem
- Velivet Triphasic Regimen (28)
- Vestura (28)
- Viorele (28)
- Vivelle-dot
- Vyfemla (28)
- Wera (28)
- Wymzya Fe
- Yasmin (28)
- Yaz 28
- Zarah
- Zenchent (28)
- Zenchent Fe
- Zeosa
- Zovia 1/35E (28)
- Zovia 1/50E (28)
- None
Contraindicated
- Hemolytic anemia
- Non-infective meningitis
- Predisposition to thrombosis
- Thromboembolic disorder
Severe
Moderate
- Atherosclerotic cardiovascular disease
- Bed-ridden
- Chronic heart failure
- Diabetes mellitus
- Hypertension
- Hypovolemia
- Increased cardiovascular event risk
- Kidney disease with reduction in GFR
- Monoclonal gammopathy
- Sepsis
- Transfusion related acute lung injury
FLEBOGAMMA DIF (IMMUNE GLOBULIN,GAMMA(IGG))
- Primary immune deficiency disorder
- Agammaglobulinemia
- Common variable agammaglobulinemia
- Idiopathic thrombocytopenic purpura
- Severe combined immunodeficiency disease
- Wiskott-aldrich syndrome
- X-linked agammaglobulinemia
- Tachycardia
- Arthralgias
- Chills
- Cough
- Diarrhea
- Dizziness
- Earache
- Edema
- Fatigue
- Fever
- Headache disorder
- Injection site sequelae
- Nausea
- Pharyngitis
- Skin rash
- Vomiting
More Frequent
Severe
Less Severe
- Dyspnea
- Wheezing
- Cramps
- Malaise
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Anaphylaxis
- Bronchospastic pulmonary disease
- Bullous dermatitis
- Cerebrovascular accident
- Chest pain
- Cyanosis
- Disseminated intravascular coagulation
- Erythema multiforme
- Hemolysis
- Hemolytic anemia
- Hyperproteinemia
- Hypertension
- Hypotension
- Kidney disease with reduction in GFR
- Leukopenia
- Migraine
- Non-infective meningitis
- Pancytopenia
- Pseudohyponatremia
- Pulmonary edema
- Pulmonary thromboembolism
- Renal failure
- Seizure disorder
- Stevens-johnson syndrome
- Thromboembolic disorder
- Thrombotic disorder
Less Severe
- Back pain
- Flushing
- General weakness
- Hematuria
- Myalgias
- Photophobia
- Pruritus of skin
- Tremor
- Urine discoloration
- Urticaria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Immune Globulin DIF (IV)
No safety and efficacy established age < 2 years.
- 1 Day – 2 Years
- No safety and efficacy established age < 2 years.
Immune Globulin,gamma (igg)
- Severity Level:
2
- Additional Notes: Insuff human/animal data avail, consider maternal tx benefit vs poss fetal risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Immune Globulin,gamma (igg)
Insufficient data available.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Immune Globulin Parenteral (human)
General-Administer at the minimum infusion rate and do not exceed recommended dose. Renal-Increased risk of acute kidney injury in patients with decreased renal function. Cardiovascular-May be at increased risk of thrombosis. Assure adequate hydration and not volume depleted. Risk increases with immobility, hyperviscosity and underlying cardiovascular risks.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Agammaglobulinemia | |
| D80.0 | Hereditary hypogammaglobulinemia |
| D80.1 | Nonfamilial hypogammaglobulinemia |
| Common variable agammaglobulinemia | |
| D80.1 | Nonfamilial hypogammaglobulinemia |
| D83 | Common variable immunodeficiency |
| D83.0 | Common variable immunodeficiency with predominant abnormalities of b-cell numbers and function |
| D83.1 | Common variable immunodeficiency with predominant immunoregulatory t-cell disorders |
| D83.2 | Common variable immunodeficiency with autoantibodies to b- or t-cells |
| D83.8 | Other common variable immunodeficiencies |
| D83.9 | Common variable immunodeficiency, unspecified |
| Idiopathic thrombocytopenic purpura | |
| D69.3 | Immune thrombocytopenic purpura |
| Primary immune deficiency disorder | |
| D84.9 | Immunodeficiency, unspecified |
| Severe combined immunodeficiency disease | |
| D81.0 | Severe combined immunodeficiency [SCId] with reticular dysgenesis |
| D81.1 | Severe combined immunodeficiency [SCId] with low t- and b-cell numbers |
| D81.2 | Severe combined immunodeficiency [SCId] with low or normal b-cell numbers |
| D81.31 | Severe combined immunodeficiency due to adenosine deaminase deficiency |
| Wiskott-aldrich syndrome | |
| D82.0 | Wiskott-aldrich syndrome |
| X-linked agammaglobulinemia | |
| D80.0 | Hereditary hypogammaglobulinemia |
| 0-9 | A-Z |
|---|---|
| D69.3 | Immune thrombocytopenic purpura |
| D80.0 | Hereditary hypogammaglobulinemia |
| D80.0 | Hereditary hypogammaglobulinemia |
| D80.1 | Nonfamilial hypogammaglobulinemia |
| D80.1 | Nonfamilial hypogammaglobulinemia |
| D81.0 | Severe combined immunodeficiency [SCId] with reticular dysgenesis |
| D81.1 | Severe combined immunodeficiency [SCId] with low t- and b-cell numbers |
| D81.2 | Severe combined immunodeficiency [SCId] with low or normal b-cell numbers |
| D81.31 | Severe combined immunodeficiency due to adenosine deaminase deficiency |
| D82.0 | Wiskott-aldrich syndrome |
| D83 | Common variable immunodeficiency |
| D83.0 | Common variable immunodeficiency with predominant abnormalities of b-cell numbers and function |
| D83.1 | Common variable immunodeficiency with predominant immunoregulatory t-cell disorders |
| D83.2 | Common variable immunodeficiency with autoantibodies to b- or t-cells |
| D83.8 | Other common variable immunodeficiencies |
| D83.9 | Common variable immunodeficiency, unspecified |
| D84.9 | Immunodeficiency, unspecified |
Formulary Reference Tool